Scarica l'app Stockscreener
9.20
0.88%
0.08
Pre-mercato:
9.35
0.15
+1.63%
10 X Genomics Inc Borsa (TXG) Ultime notizie
'Shooting ourselves in the foot': Trump administration cuts force East Bay’s 10x Genomics into layoffs - The Business Journals
NanoString to pay 10x Genomics $68m in global settlement - Life Sciences Intellectual Property Review
10x Genomics reaches settlement with Bruker - Medical Buyer
Stifel Financial Corp Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $12.00 - Defense World
10x Genomics Reaches $68 Million Patent Settlement With Bruker - marketscreener.com
10x Genomics Settles Litigation with Bruker Corporation - TipRanks
10x Genomics settles patent dispute with Bruker for $68 million - Investing.com
10x Genomics Wins Massive $68M Settlement Plus Royalties in Major Patent Battle with Bruker - Stock Titan
All Ongoing Lawsuits Between Bruker And 10X Genomics To Be Withdrawn - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96 - simplywall.st
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Chal - GuruFocus
Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech
10x Genomics, Bruker Strike Deal After $31M Patent Verdict - Law360
10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News - GuruFocus
UPC battle between 10x Genomics and Curio Bioscience moves to next stage - JUVE Patent
UBS Adjusts Price Target on 10x Genomics to $12 From $14, Maintains Neutral Rating - marketscreener.com
10x Genomics (NASDAQ:TXG) Price Target Lowered to $6.50 at The Goldman Sachs Group - Defense World
10x Genomics (NASDAQ:TXG) Price Target Cut to $15.00 by Analysts at Canaccord Genuity Group - Defense World
10x Genomics (TXG) Price Target Lowered by Canaccord Genuity | T - GuruFocus
Analyst Expectations For 10x Genomics's Future - Benzinga
Canaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News - GuruFocus
JPMorgan Chase & Co. Cuts 10x Genomics (NASDAQ:TXG) Price Target to $9.00 - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
10x Genomics (NASDAQ:TXG) Shares Gap Up – Time to Buy? - Defense World
10x Genomics (NASDAQ:TXG) Receives Sell (E+) Rating from Weiss Ratings - Defense World
10x Genomics First Quarter 2025 Earnings: Beats Expectations - simplywall.st
30,005 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Raymond James Financial Inc. - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Q1 2025 Earnings Call Transcript - Insider Monkey
JPMorgan Adjusts Price Target for 10x Genomics (TXG) Amid Market Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Price Target Lowered to $9 by JP Morgan | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain O - GuruFocus
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Conc - GuruFocus
Deutsche Bank Adjusts Price Target on 10x Genomics to $10 From $16, Maintains Hold Rating - marketscreener.com
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain Outlook | TXG Stock News - GuruFocus
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigat - GuruFocus
10x Genomics (NASDAQ:TXG) adds US$65m to market cap in the past 7 days, though investors from five years ago are still down 89% - simplywall.st
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics Reports First Quarter 2025 Financial Results - BioSpace
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives - GuruFocus
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance - Benzinga
10x Genomics: Q1 Earnings Snapshot - CTPost
Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
10x Genomics’s (NASDAQ:TXG) Q1: Strong Sales But Quarterly Revenue Guidance Significantly Misses Expectations - Yahoo Finance
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics Announces Workforce Reduction to Cut Costs - TipRanks
10x Genomics Inc Q1 2025 Earnings: EPS of -$0.28 Beats Estimate, Revenue Surges to $154.9 Million - GuruFocus
Earnings Flash (TXG) 10x Genomics Posts Q1 Loss $-0.28 Per Share, vs. FactSet Est of $-0.47 - marketscreener.com
10x Genomics (NASDAQ:TXG) shareholders have endured a 90% loss from investing in the stock five years ago - Yahoo Finance
10x Genomics (TXG) Reports Q1: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Spatial Proteomics Market Future Business Opportunities - openPR.com
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Envestnet Asset Management Inc. Has $1.20 Million Position in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference - BioSpace
Sumitomo Mitsui Trust Group, Inc. Reduces Stake in 10x Genomics Inc - GuruFocus
10x Genomics to Participate in the BofA Securities 2025 Healthca - GuruFocus
10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference – Company Announcement - Financial Times
Unlocking single cell RNA profiling at multicentre clinical trials: New methods for whole blood preservation - Fierce Biotech
10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by JPMorgan Chase & Co. - Defense World
Advancing the Future of Biomarker-Driven Immunotherapy - Fierce Biotech
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis (PR Newswire) - Aktiellt
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
1.68%
1.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):